You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-cell maturation antigen (BCMA)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in New York (Ide-cel (bb2121))

Recruiting
  • Multiple Myeloma
  • Ide-cel (bb2121)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 6, 2022

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Not yet recruiting
  • Multiple Myeloma
  • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jan 13, 2023

ITP Trial in Suzhou (autologous anti-BCMA chimeric antigen receptor T cells)

Recruiting
  • ITP
  • autologous anti-BCMA chimeric antigen receptor T cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 31, 2022

Identify Barriers to Cellular Therapies for People With Plasma

Recruiting
  • Multiple Myeloma
  • Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
  • +5 more
  • Basking Ridge, New Jersey
  • +6 more
Nov 6, 2023

Multiple Myeloma Trial in Sanhe (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Not yet recruiting
  • Multiple Myeloma
  • BCMA/CD19 dual-target CAR-T cell immunotherapy
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jun 1, 2020

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

Myeloma, Plasma-Cell, Myeloma-Multiple Trial run by the NCI (Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen

Completed
Has Results
  • Myeloma, Plasma-Cell
  • Myeloma-Multiple
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 20, 2019

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

Multiple Myeloma Trial (Linvoseltamab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 12, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Multiple Myeloma Trial in Spain (REGN5458, Daratumumab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Athens, Greece
  • +8 more
Nov 30, 2022

Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

Not yet recruiting
  • Lymphomas
  • B-cell Lymphomas
  • Houston, Texas
    The University of Texas M D Anderson Cancer Center
Mar 6, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Refractory or Relapsed Multiple Myeloma Trial (LCAR-B38M CAR-T cell injection)

Unknown status
  • Refractory or Relapsed Multiple Myeloma
  • LCAR-B38M CAR-T cell injection
  • (no location specified)
Aug 31, 2021

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

B-type Chronic Lymphocytic Leukemia Subgroups: Maturation Stage

Active, not recruiting
  • Chronic Lymphocytic Leukemia
    • Manhasset, New York
      Feinstein Institute for Medical research
    Jul 6, 2022